All In Biotech

Free tool

FAERS Monitor: Renacidin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019481 or its brand name (Renacidin, Citric Acid, Gluconolactone, Magnesium Carbonate). Reports on generic versions are filed under their own applications.

Reports

17

Serious

14

82% of reports

Hospitalization

9

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • cardio-respiratory arrest2
  • device failure2
  • fall2
  • haematuria2
  • nephrolithiasis2
  • septic shock2
  • urinary tract infection2
  • acute respiratory distress syndrome1
  • apnoea1
  • aspiration1
  • asthenia1
  • balance disorder1
  • bladder perforation1
  • blood magnesium increased1
  • blood sodium decreased1

Reports by year received

View as table
YearReports
20082
20101
20121
20131
20141
20163
20173
20202
20231
20241
20251

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,142 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
bladder perforation13208.5477.9799
blood magnesium increased11374.6205.1342
device failure2162.544.2180
apnoea1158.923.739
aspiration1113.016.927
haematuria272.319.778
acute respiratory distress syndrome170.010.417
blood sodium decreased165.79.815
cardio-respiratory arrest259.216.164
septic shock256.915.561
nephrolithiasis254.014.758
urinary tract infection214.53.914
balance disorder114.32.13
fall27.42.06
asthenia13.30.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.